Full access
Government News
Published Online: 2 April 2004

Texas Boots Antipsychotic From Preferred List

Kate MulliganAuthors Info & Affiliations
Publication: Psychiatric News
Volume 39, Number 7
https://doi.org/10.1176/pn.39.7.0009a
Track CitationsAdd to favorites
Texas recently excluded Zyprexa, a second-generation antipsychotic sold by Eli Lilly and Co., from its Medicaid preferred drug list (PDL).
Texas physicians are now required to receive prior authorization before prescribing drugs that are not on the PDL.
According to the March 1 Wall Street Journal, a committee of pharmacists and physicians advised the state’s Medicaid program to include the antipsychotics Risperdal (risperdal), Abilify (aripiprazole), Seroquel (quetiapine), and Geodon (ziprasidone) on the list.
Reporter Leila Abboud wrote that Zyprexa is the most expensive atypical antipsychotic on the market and that in 2003 the drug accounted for $86 million of Texas’s expenditure of $187 million on second-generation antipsychotics.
Kentucky and West Virginia previously removed Zyprexa from their PDLs.
The actions in those states signify a change, because antipsychotic medications in most states have been exempt from requirements for prior authorization.
With increased strains on Medicaid budgets, however, state officials are taking a serious look at ways to reduce or stabilize the cost of antipsychotic medications (see pages 19 and 20).
Those sales are important to pharmaceutical companies.
Richard Frank, Ph.D., a professor in the department of health care policy at Harvard Medical School, told Psychiatric News, “In 2001, Medicaid programs bought 70 percent of all antipsychotic medications purchased in the United States.”
An article in the February 1 New York Times described how state government officials have become the target of various “marketing tactics” by pharmaceutical companies because of the financial importance of sales of antipsychotic medication to Medicaid programs.
Psychiatric News will report developments regarding changes in access to antipsychotic medications through Medicaid. Please send information on this topic by e-mail to [email protected] with a copy to Karen Sanders of the APA Office of Healthcare Systems and Financing at [email protected]. ▪

Information & Authors

Information

Published In

Go to Psychiatric News
Psychiatric News
Volume 39 • Number 7 • April 2, 2004
Pages: 9 - 10

History

Published online: 2 April 2004
Published in print: April 2, 2004

Notes

Several states are moving toward requiring prior authorization before patients can receive antipsychotic medications through the Medicaid program.

Authors

Details

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard
Tips for downloading citations

View Options

View options

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share

×

As described within the American Psychiatric Association (APA)'s Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences. Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.